Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on June 12, 2007
JNCI Journal of the National Cancer Institute 2007 99(12):974-975; doi:10.1093/jnci/djm006
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/12/974    most recent
djm006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Feldman, D. R.
Right arrow Articles by Motzer, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feldman, D. R.
Right arrow Articles by Motzer, R. J.
Related Collections
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

CORRESPONDENCE

Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Darren R. Feldman, Andrew J. Martorella, Richard J. Robbins, Robert J. Motzer

Affiliations of authors: Division of Medical Oncology and Hematology (DRF), Endocrinology Service (AJM), and Genitourinary Oncology Service, Division of Solid Tumor Oncology (RJM), Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Medicine, The Methodist Hospital, Houston, TX (RJR)

Correspondence to: Robert J. Motzer, MD, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021 (e-mail: motzerr@mskcc.org.

The first 10% of the full text of this article appears below.

Rini et al. (1) report on the incidence of hypothyroidism in patients treated with sunitinib for metastatic renal cell carcinoma. These authors found a high (85%) rate of abnormalities in the thyroid function tests of patients with renal cell carcinoma who were treated with sunitinib. In addition, they noted that 84% of patients with abnormal thyroid function tests experienced symptoms possibly related to hypothyroidism. These findings support a recent report by Desai et al. (2), in which 62% of patients had an abnormal . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Response to this Correspondence

Response: Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini
J Natl Cancer Inst 2007 99: 976-977. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
P Iglesias and J J Diez
Thyroid dysfunction and kidney disease
Eur. J. Endocrinol., April 1, 2009; 160(4): 503 - 515.
[Abstract] [Full Text] [PDF]